LinkoCare is a knowledge-intensive private limited company registered (Organization number 556947-8398) and operating in Sweden with the primary mission of further development and commercialization of bioengineered corneas to help restore sight to millions of people around the world suffering from corneal blindness and low vision. The company has also developed in vitro tissue mimetic membranes for Research and Development (R&D) applications for boosting stem cells growth as well as an alternative to animal testing. The company’s mandate is to establish itself as a world leader in the field of bioengineered products and a knowledge hub for R&D. LinkoCare's long-term goal is to provide the vision, strategy, and management capability for further development and commercialization of bioengineered medical devices platforms including Tissue-Engineered Medical Products (TEMP), Hybrid Medical Devices, and Advanced Therapy Medicinal Products (ATMP) for a wide-range of medical uses focusing on ophthalmic, cardiac, and nerve regeneration applications. LinkoCare is currently building next generation bioengineered corneas and refractive devices for sight restoration and correction as well as tissue mimetic membranes.